Investments, Debt and Equity Securities [Abstract] Maturing in one year or less Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Maturing after one year through five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Total investments available-for-sale Debt Securities, Available-for-sale Earnings Per Share [Abstract] Computation of Basic and Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Subsequent Events [Abstract] Subsequent Event Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements [Domain] Lease Arrangements [Domain] [Domain] for Lease Arrangements [Axis] Built-To-Suit Lease Built-To-Suit Lease [Member] Built-To-Suit Lease [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Alameda, California Alameda, California [Member] Alameda, California [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Area of lease property (in square feet) Area of Real Estate Property Operating lease term Lessee, Operating Lease, Term of Contract Estimated monthly base rent under Build-to-Suite Leases Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment Monthly base rent, lease not yet commenced, annual percentage increase Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage Number of options to extend the Lease Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Lease option to extend period Lessee, Operating Lease, Renewal Term Option to terminate lease (after period) Lessee, Operating Lease, Option To Terminate After Period Lessee, Operating Lease, Option To Terminate After Period Operating lease, expansion (in square feet) Operating Lease, Additional Area Of Real Estate Property Operating Lease, Additional Area Of Real Estate Property Property, Plant and Equipment [Abstract] Depreciation expense Depreciation Inventory Disclosure [Abstract] Inventory, Current [Table] Inventory, Current [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Current portion included in Inventory Inventories [Member] Long-term portion included in Other long-term assets Other Long-term Assets [Member] Other Long-term Assets [Member] Inventory [Line Items] Inventory [Line Items] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total Inventory, Gross Write-downs on inventory Inventory Write-down Share-based Payment Arrangement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Stock Options Share-based Payment Arrangement, Option [Member] RSUs Restricted Stock Units (RSUs) [Member] PSUs Performance Shares [Member] PSUs, achieved before December 31, 2020 Performance Shares, Achieved Before December 31, 2020 [Member] Performance Shares, Achieved Before December 31, 2020 [Member] PSUs, second product approval Performance Shares, Second Product Approval [Member] Performance Shares, Second Product Approval [Member] Status [Axis] Status [Axis] Status [Axis] Status [Domain] Status [Domain] [Domain] for Status [Axis] Achieved Achieved [Member] Achieved [Member] Probable Probable [Member] Probable [Member] Not Probable Not Probable [Member] Not Probable [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Weighted-average cost recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition RSUs awarded (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Maximum potential to vest, percentage Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest Maximum potential to vest (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest Product revenue related performance targets, shares vested and released (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Compensation expense Share-based Payment Arrangement, Expense Statement of Financial Position [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Shares authorized (in shares) Preferred Stock, Shares Authorized Shares issued (in shares) Preferred Stock, Shares Issued Common stock Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Par value (in dollars per share) Common Stock, Par or Stated Value Per Share Shares authorized (in shares) Common Stock, Shares Authorized Shares issued (in shares) Common Stock, Shares, Issued Shares outstanding (in shares) Common Stock, Shares, Outstanding Fair Value Disclosures [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Money market funds Money Market Funds [Member] Commercial paper Commercial Paper [Member] Corporate bonds Corporate Bond Securities [Member] U.S. Treasury and government sponsored enterprises US Treasury and Government [Member] Certificates of deposit Certificates of Deposit [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring Fair Value, Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total investments available-for-sale Certificates of deposit Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure Total financial assets carried at fair value Assets, Fair Value Disclosure Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] GSK Glaxo Smith Kline [Member] Glaxo Smith Kline [Member]. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement with Ipsen Collaborative Arrangement with Ipsen [Member] Collaborative Arrangement with Ipsen [Member] Collaboration Agreement with GlaxoSmithKline Collaborative Arrangements with Glaxo Smith Kline [Member] Collaborative Arrangements with Glaxo Smith Kline Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Percent of royalty on net sale Collaboration Agreement, Percent Of Royalty On Net Sale Collaboration Agreement, Percent Of Royalty On Net Sale Royalties accruing to GSK Royalty Expense STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Reconciliation of Cash, Cash Equivalents, and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Reconciliation of Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Investments by Security Type Unrealized Gain (Loss) on Investments [Table Text Block] Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block] Fair Value of Cash Equivalents and Investments by Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Investment [Table] Investment [Table] Cash and restricted cash Cash And Restricted Cash [Member] Cash And Restricted Cash [Member] Investment [Line Items] Investment [Line Items] Investments, available-for-sale, Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Investments available-for-sale, Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Investments available-for-sale, Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Investments available-for-sale, Fair Value Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents, and restricted cash, Gross Unrealized Gains Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain Cash, cash equivalents, and restricted cash, Gross Unrealized Losses Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss Cash, restricted cash and certificates of deposit, Fair Value Total cash and investments, Amortized Cost Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis Total cash and investments, Gross Unrealized Gains Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax Total cash and investments, Gross Unrealized Losses Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax Total cash and investments, Fair Value Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities Stock options ESPP Employee Stock [Member] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Statement of Cash Flows [Abstract] Net income Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Stock-based compensation Share-based Payment Arrangement, Noncash Expense 401(k) matching contributions made in common stock Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash Amortization and other changes in right-of-use assets Right-Of-Use Asset, Amortization Right-of-Use Asset, Amortization Deferred income taxes Increase (Decrease) in Deferred Income Taxes Gain on other equity investments Gain (Loss) on Sale of Other Investments Accretion of investments, net and other Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Trade receivables, net Increase (Decrease) in Accounts Receivable Other receivables Increase (Decrease) in Other Receivables Inventory, net Increase (Decrease) in Inventories Current portion of unbilled collaboration revenue Increase (Decrease) in Contract with Customer, Asset Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other long-term assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Accrued clinical trial liabilities Increase (Decrease) In Accrued Clinical Liabilities Increase (decrease) in accrued clinical liabilities Rebates and fees due customers Increase (Decrease) In Rebates And Fees Payable Increase (Decrease) In Rebates And Fees Payable Accrued collaboration liability Increase (Decrease) In Accrued Collaboration Liability Increase (Decrease) in Accrued Collaboration Liability Current and long-term deferred revenue Increase (Decrease) in Contract with Customer, Liability Long-term portion of lease liabilities Increase (Decrease) In Lease Liability, Noncurrent Increase (Decrease) In Lease Liability, Noncurrent Other current and long-term liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Purchases of investments Payments to Acquire Debt Securities, Available-for-sale Proceeds from maturities of investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Proceeds from sale of investments Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from other equity investments Proceeds from Sale and Maturity of Other Investments Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Proceeds from employee stock purchase plan Proceeds from Stock Plans Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Principal payments on financing lease obligation Repayments of Long-term Capital Lease Obligations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental cash flow disclosure: Supplemental Cash Flow Information [Abstract] Right-of-use assets obtained in exchange for lease obligations Right-Of-Use Asset Obtained In Exchange For Lease Liability Right-Of-Use Asset Obtained In Exchange For Lease Liability Unpaid liabilities incurred to acquire Property and equipment Capital Expenditures Incurred but Not yet Paid Unpaid liabilities incurred to acquire investments Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions Collaborative Arrangement with Genentech Collaborative Arrangement with Genentech [Member] Collaborative Arrangement with Genentech [Member] Profits and losses on U.S. commercialization Collaborative Arrangement, Income (Loss) From Agreement Collaborative Arrangement, Income (Loss) from Agreement Royalty revenues on ex-U.S. sales Revenue from Contract with Customer, Excluding Assessed Tax Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation Leases [Abstract] LEASES Lessee, Operating Leases [Text Block] LEASES Lessee, Finance Leases [Text Block] Income Tax Disclosure [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Net unrealized gains or losses on available-for-sale securities, net of tax impact of $___, $0, $___ and $0, respectively Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] U.S. UNITED STATES Europe Europe [Member] Japan JAPAN Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total revenues Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Net product revenues Product [Member] CABOMETYX Cabometyx [Member] Cabometyx [Member] COMETRIQ Cometriq [Member] Cometriq [Member] Net product revenues Weighted average grant-date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Numerator: Earnings Per Share, Numerator [Abstract] Earnings Per Share, Numerator [Abstract] Denominator: Earnings Per Share, Denominator [Abstract] Earnings Per Share, Denominator [Abstract] Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Dilutive securities (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Net income per share, basic (in dollars per share) Earnings Per Share, Basic Net income per share, diluted (in dollars per share) Earnings Per Share, Diluted Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASU No. 2014-09 Accounting Standards Update 2014-09 [Member] ASU No. 2016-02 Accounting Standards Update 2016-02 [Member] Statement [Line Items] Statement [Line Items] Balance (in shares) Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Adoption of Accounting Standards Update No's. (2014-09 and 2016-02) Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income (loss) Issuance of common stock under equity incentive and stock purchase plans (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Issuance of common stock under equity incentive and stock purchase plans Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Balance (in shares) Balance SUBSEQUENT EVENTS Subsequent Events [Text Block] Unbilled collaboration revenue Contract with Customer, Asset, Net, Current Deferred revenue Contract with Customer, Liability, Noncurrent Amount of revenues recognized included in the beginning contract liability balance Contract with Customer, Liability, Revenue Recognized Revenues recognized for performance obligations satisfied in previous periods Contract with Customer, Performance Obligation Satisfied in Previous Period INVENTORY Inventory Disclosure [Text Block] Balance Sheet Classification of Lease Liabilities Lessee, Operating And Financing Lease Liabilities [Table Text Block] Lessee, Operating And Financing Lease Liabilities [Table Text Block] Components of Lease Expense Lease, Cost [Table Text Block] Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract] Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract] In an Unrealized Loss Position Less than 12 Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss In an Unrealized Loss Position 12 Months or Greater, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Total, Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position Total, Gross Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Chargebacks and Discounts for Prompt Payment Chargebacks And Discounts For Prompt Payment [Member] Chargebacks And Discounts For Prompt Payment [Member] Other Customer Credits/Fees and Co-pay Assistance Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member] Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member] Rebates Allowance For Product Rebates [Member] Allowance For Product Rebates [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Balance at December 31, 2018 SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Provision related to sales made in: Valuation Allowances And Reserves, Additions To Provision [Abstract] Valuation Allowances And Reserves, Additions To Provision [Abstract] Current period Valuation Allowances And Reserves, Additions For Sales In Current Period Valuation Allowances And Reserves, Additions For Sales In Current Period Prior periods Valuation Allowances And Reserves, Additions For Sales In Prior Period Valuation Allowances And Reserves, Additions For Sales In Prior Period Payments and customer credits issued SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Balance at September 30, 2019 COLLABORATION AGREEMENTS Collaborative Arrangement Disclosure [Text Block] Operating lease liabilities: Operating Lease Liabilities [Abstract] Operating Lease Liabilities [Abstract] Current portion included in Other current liabilities Operating Lease, Liability, Current Long-term portion of lease liabilities Operating Lease, Liability, Noncurrent Total operating lease liabilities Operating Lease, Liability Financing lease liabilities: Financing Lease Liabilities [Abstract] Financing Lease Liabilities [Abstract] Current portion included in Other current liabilities Finance Lease, Liability, Current Long-term portion of lease liabilities Finance Lease, Liability, Noncurrent Financing obligation for build-to-suit lease Finance Lease, Liability Total lease liabilities Operating And Finance Leases, Liability - Total Operating And Finance Leases, Liability - Total Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] Operating lease cost Operating Lease, Cost Variable lease cost Variable Lease, Cost Total lease costs Lease, Cost Collaboration Agreement with Iconic Therapeutics, Inc. Collaboration Agreement With Iconic Therapeutics, Inc. [Member] Collaboration Agreement With Iconic Therapeutics, Inc. [Member] Upfront payment Collaboration Agreements, Upfront Payments Collaboration Agreements, Upfront Payments Preclinical development funding commitment accrued Collaboration Agreement, Research And Development Expense Accrued Collaboration Agreement, Research And Development Expense Accrued Option exercise fee payment, if exercised Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option Maximum amount eligible for development, regulatory and first-sale milestones Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones Maximum amount eligible for development and regulatory milestones under collaborations agreement. Maximum amount eligible for commercial milestones under collaborations agreement Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement Collaborative Arrangement with Takeda Collaborative Arrangement with Takeda [Member] Collaborative Arrangement with Takeda [Member] Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] NET INCOME PER SHARE Earnings Per Share [Text Block] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent U.S. federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Trade receivables, net Receivables, Net, Current Other receivables Other Receivables, Net, Current Inventory, net Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Long-term investments Long-term Investments Long-term restricted cash and investments Restricted Cash, Noncurrent Property and equipment, net Property, Plant and Equipment, Net Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Deferred tax assets, net Deferred Income Tax Assets, Net Goodwill Goodwill Other long-term assets Other Assets, Noncurrent Total assets Assets Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation and benefits Accrued Employee Benefits, Current Accrued clinical trial liabilities Accrued Clinical Liabilities, Current Accrued Clinical Liabilities, Current Rebates and fees due to customers Customer Refund Liability, Current Accrued collaboration liabilities Accrued Collaboration Liability, Current Accrued Collaboration Liability, Current Other current liabilities Other Accrued Liabilities, Current Total current liabilities Liabilities, Current Long-term portion of lease liabilities Operating And Finance Leases, Liability - Long Term Operating And Finance Leases, Liability - Long Term Long-term portion of deferred revenue Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments Commitments and Contingencies Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued Preferred Stock, Value, Issued Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 303,776,032 and 299,876,080 at September 30, 2019 and December 31, 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Total liabilities and stockholders’ equity Liabilities and Equity Allocated Employee Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Valuation Assumptions Used to Estimate Grant-Date Fair Value Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] RSU Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Inventory Schedule of Inventory, Current [Table Text Block] Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member] Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Collaboration agreement, number of programs Collaboration Agreement, Number Of Programs Collaboration Agreement, Number Of Programs Collaboration agreement, number of preexisting programs Collaboration Agreement, Number Of Preexisting Programs Collaboration Agreement, Number Of Preexisting Programs Collaboration agreement, number of drug discovery programs Collaboration Agreement, Number Of Drug Discovery Programs Collaboration Agreement, Number Of Drug Discovery Programs Additional option payments Collaboration Agreement, Additional Option Payments Collaboration Agreement, Additional Option Payments Research and development obligation Collaboration Agreement, Research And Development Obligation Collaboration Agreement, Research And Development Obligation Maximum amount eligible for development and regulatory milestones Property and Equipment Property, Plant and Equipment [Table Text Block] Basis of Consolidation Consolidation, Policy [Policy Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Fiscal Period Fiscal Period, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Revenues Revenue from Contract with Customer [Policy Text Block] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Ipsen Ipsen [Member] Ipsen [Member] Caremark L.L.C. Caremark L.L.C. [Member] Caremark L.L.C. [Member] Affiliates of McKesson Corporation Affiliates of McKesson Corporation [Member] Affiliates of McKesson Corporation [Member] Affiliates of AmerisourceBergen Corporation ASD [Member] ASD [Member] Others, individually less than 10% of Total revenues for all periods presented Other Customers [Member] Other Customers [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue Revenue from Contract with Customer Benchmark [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Percent of total revenues Concentration Risk, Percentage Income Statement [Abstract] Collaboration revenue Collaboration [Member] Collaboration [Member] Operating expenses: Operating Expenses [Abstract] Cost of goods sold Cost of Goods and Services Sold Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other income (expense), net: Nonoperating Income (Expense) [Abstract] Interest income Interest Income, Other Other, net Other Nonoperating Income (Expense) Total other income (expense), net: Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net income Shares used in computing net income per share, basic (in shares) Shares used in computing net income per share, diluted (in shares) Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Net contract liability FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Cash and Cash Equivalents [Abstract] Cash and cash equivalents Restricted cash included in short-term restricted cash and investments Restricted Cash, Current Restricted cash included in long-term restricted cash and investments Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Potentially dilutive securities Share-based Payment Arrangement [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount CASH AND INVESTMENTS Cash, Cash Equivalents, and Investments [Text Block] Cash, Cash Equivalents, and Investments [Text Block] Unrealized gains or losses on available-for-sale securities, tax impact Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Reclassification adjustments to net income resulting from realized gains or losses on sale of securities Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax REVENUES Revenue from Contract with Customer [Text Block] Collaboration Agreement with Daiichi Sankyo Collaboration Agreement with Daiichi Sankyo [Member] Collaboration Agreement with Daiichi Sankyo [Member] Gain (loss) on sales of investments available-for-sale Debt Securities, Available-for-sale, Realized Gain (Loss) Number of investments in an unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Other-than-temporary impairment charges on available-for-sale securities Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale Beneficial ownership interest by BlackRock (more than) Ownership Interest By Minority Shareholder Minority Ownership, Ownership Interest Fair value of cash and investments managed by BlackRock Related Party Transactions, Cash And Investments Managed By Minority Owner Related Party Transactions, Cash And Investments Managed By Minority Owner Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund Payable to BlackRock Due to Related Parties, Current Fees for advisory services paid to BlackRock Related Party Transactions, Advisory Fees Incurred Related Party Transactions, Advisory Fees Incurred Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Leasehold improvements Leasehold Improvements [Member] Computer equipment and software Computer Equipment And Software [Member] Computer Equipment And Software [Member]. Furniture and fixtures Furniture and Fixtures [Member] Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Construction in progress Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Options outstanding at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Options outstanding at end of period (in dollars per share) Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract] Options outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Options outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Tenant improvement reimbursements Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements Operating lease, surrendered (in square feet) Operating Lease, Surrendered Area Of Real Estate Property Operating Lease, Surrendered Area Of Real Estate Property Tenant improvement allowance Tenant Lease Improvements, Allowance Tenant Lease Improvements, Allowance Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Weighted average operating discount rate used to determine the operating lease liability Operating Lease, Weighted Average Discount Rate, Percent Weighted average remaining lease term for operating lease Operating Lease, Weighted Average Remaining Lease Term Net product revenues Gross product revenues Product, Gross [Member] Product, Gross [Member] Discounts and allowances Sales Discounts And Allowances [Member] Sales Discounts And Allowances [Member] Total collaboration revenues License revenues License [Member] Research and development services revenues Research and Development [Member] Research and Development [Member] Other collaboration revenues Other Collaboration [Member] Other Collaboration [Member] Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Payment, Due [Abstract] Remainder of 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Years ending December 31, Operating Lease Liabilities, Duration Of Maturity [Abstract] Operating Lease Liabilities, Duration Of Maturity [Abstract] 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Lessee, Operating Lease, Reduction Of Payments Due [Abstract] Lessee, Operating Lease, Reduction Of Payments Due [Abstract] Present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Tenant improvement reimbursements Operating lease liabilities Organization And Summary Of Significant Policies [Table] Organization And Summary Of Significant Policies [Table] Organization And Summary Of Significant Policies [Table] Products Derived from Cabozantinib Products Derived From Cabozantinib [Member] Products Derived from Cabozantinib [Member] Resulting from Discovery Efforts Resulting From Discovery Efforts [Member] Resulting From Discovery Efforts [Member] Organization And Summary Of Significant Policies [Line Items] Organization And Summary Of Significant Policies [Line Items] Organization And Summary Of Significant Policies [Line Items] Number of products that entered in the commercial marketplace Number of Products in Commercial Market Number of Products in Commercial Market Number of business segments Number of Operating Segments Schedule of Collaborative Revenues Under Collaboration Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Limit on reimbursement per year Collaborative Arrangement, Annual Reimbursement Limit Collaborative Arrangement, Annual Reimbursement Limit Increase in maximum amount eligible for development and regulatory milestones Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones Milestone payments earned Collaboration Agreement, Milestone Payments Earned Collaboration Agreement, Milestone Payments Earned Increase in maximum amount eligible for commercial milestones under collaborations agreement Increase (Decrease) In Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement Increase in Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement Net contract liability Contract with Customer, Liability Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] RSUs outstanding at beginning of period (in shares) Awarded (in shares) Vested and released (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period RSUs outstanding at end of period (in shares) Weighted Average Grant Date Fair Value Per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] RSUs outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Awarded (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested and released (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value RSUs outstanding at end of period (in dollars per share) Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract] Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract] RSUs outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] RSUs outstanding at end of period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.